Pulse Biosciences Q2 Loss Widens to $24.7M, ATM Raises $46.8M
PLSE has more than doubled off its 52-week low of $12.56.
Summary
Pulse Biosciences reported a Q2 net loss of $24.66 million, wider than the prior year, driven by higher clinical and compensation expenses. The company raised $46.8 million in net proceeds through its ATM program, strengthening its cash position. Sequential revenue growth was noted during a controlled commercial launch. Enrollment in the NANOPULSE-AF pivotal study is expected to complete by early Q4 2026, with CE Mark submissions for cardiac catheter and surgical systems planned for H2 2026. The NANOCLAMP-AF study enrollment is targeted for completion by end of H1 2027. This follows the $12.9 million insider-led ATM raise in Q1 and the recent warrant redemption, indicating continued insider support and capital access.
At the time of this announcement, PLSE was trading at $36.23 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.6B. The 52-week trading range was $12.56 to $39.12. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Reuters.